Welcome to our dedicated page for VLON news (Ticker: VLON), a resource for investors and traders seeking the latest updates and insights on VLON stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VLON's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VLON's position in the market.
Vallon Pharmaceuticals (NASDAQ: VLON) has successfully completed its initial public offering of 2,250,000 shares at a price of $8.00 per share, generating gross proceeds of $18 million. The offering closed on February 12, 2021, following the stock's debut on the Nasdaq Capital Market on February 10, 2021. The company has granted underwriters a 45-day option to purchase an additional 337,500 shares. Vallon's focus lies in developing drugs to deter abuse in CNS disorders, with their lead product candidate, ADAIR, aimed at treating ADHD and narcolepsy.
Vallon Pharmaceuticals has announced the pricing of its IPO, offering 2,250,000 shares at $8.00 each, totaling $18 million in gross proceeds. The shares will trade on The Nasdaq Capital Market under the ticker symbol VLON starting February 10, 2021, with closure expected on February 12, 2021. The offering includes an additional 337,500 shares option for underwriters. Vallon focuses on developing abuse-deterrent medications for CNS disorders, with its lead candidate being a formulation for ADHD and narcolepsy.